Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Pacing Clin Electrophysiol ; 45(3): 297-301, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35172014

RESUMO

BACKGROUND: The displacement of cardiac implantable electronic devices (CIEDs) toward the caudal side during standing after CIED implantation could cause lead dislodgement. This study investigated the relationship between supine pocket position and standing CIEDs' displacement distance after the implantation. METHODS: After CIED surgeries performed at 2 hospitals between 2012 and 2020, 134 patients underwent postoperative chest x-rays in the supine and standing positions during hospitalization. To measure the displacement distance of CIEDs from the supine to the standing position, we identified the first thoracic vertebrae (Th1) in the supine position using the first rib as an index, drew a horizontal line at the lower edge of the Th1, and calculated the distance from that point to the upper edge of the CIED. The difference between measures for the two positions was compared. At the position of the pocket in the thorax in the supine position, the ratio of the distance between the thorax and the device is defined as the device thorax ratio (DTR). We examined the relationship between DTR and CIED displacement distance. RESULTS: In this study, we included 134 patients (53% men; median age, 79 years, body mass index, 22.3 ± 3.4; pacemaker 93%, left implantation 96%). We found that the more lateral the position of the CIED pocket, the more the CIED fell when standing (confidence interval = 0.34-0.60, P < .001). CONCLUSIONS: The farther the CIED was implanted outside the thorax in the supine position, the more significantly the CIED was displaced in the standing position.


Assuntos
Desfibriladores Implantáveis , Marca-Passo Artificial , Idoso , Feminino , Humanos , Masculino , Estudos Retrospectivos , Posição Ortostática , Tórax
2.
Fukuoka Igaku Zasshi ; 98(6): 260-9, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17665547

RESUMO

BACKGROUND: As statins have the anti-atherosclerotic pleiotropic effects, we retrospectively examined the effects of statins on restenosis after percutaneous coronary intervention (PCI). METHODS: We reviewed consecutive 341 patients who underwent successful PCI and follow-up angiography six months after the procedure between January 2002 and December 2004. Statins were initiated in 207 patients (statin group), but not in the other 134 (control group). We compared the angiographic findings, low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) between the two groups. RESULTS: LDL-C level in statin group was significantly higher than those in control group at baseline (116.0 +/- 35.8 vs 103.1 +/- 24.5 mg/dL, p < 0.01); however, the values were inverted between the two groups at follow-up (99.9 +/- 29.5 vs 107.6 +/- 26.0 mg/dL, p = 0.015). CRP levels were comparable between these two groups. Statin group showed significantly lower angiographic restenosis (defined as > or = 50% stenosis at the target site) rate (35.3 vs 46.3%, p = 0.042) and target lesion revascularization (TLR) rate (14.5 vs 23.9%, p = 0.018) than control group. Multivariate analysis indicated that the prescription of statin, but not LDL-C level at follow-up and % reduction of LDL-C during the follow-up period, predict the restenosis prevention. CONCLUSIONS: Statins can decrease restenosis and TLR rate after PCI, independent of lipid-lowering effect and CRP level in this study.


Assuntos
Angioplastia Coronária com Balão , Proteína C-Reativa/análise , LDL-Colesterol/sangue , Doença da Artéria Coronariana/terapia , Reestenose Coronária/prevenção & controle , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Idoso , Biomarcadores/sangue , Angiografia Coronária , Reestenose Coronária/diagnóstico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estudos Retrospectivos
3.
Fukuoka Igaku Zasshi ; 97(2): 37-41, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16642955

RESUMO

We here report a case of 71-year-old man with acute extensive anterior myocardial infarction, who was complicated with ventricular tachycardia (VT) even after successful percutaneous coronary intervention. As intravenous administration of nifekalant terminated VT, we started oral administration of amiodarone (day 1). We gave 400 mg of amiodarone a day for the first week and 200 mg a day from the second week. The patient was stable with normoxia by day 20, in spite of pulmonary congestion-like infiltrates on chest X-ray. On day 21, he was complicated with acute respiratory distress syndrome. Immediate discontinuance of amiodarone and high-dose pulse glucocorticoid therapy with intubation slightly improved the infiltrations on chest X-ray. However, glucocorticoid therapy induced hyperglycemia with an increase in plasma osmolality, complicated with hypoalbuminemia, and gastrointestinal bleeding. Despite treatment with a large amount of saline, high-doses of catecholamines, and blood transfusion, the patient died on day 28. It is sometimes difficult to diagnose congestive heart failure or amiodarone-induced pulmonary infiltrates in patients with severe left ventricular dysfunction.


Assuntos
Amiodarona/efeitos adversos , Antiarrítmicos/efeitos adversos , Infarto do Miocárdio/complicações , Síndrome do Desconforto Respiratório/induzido quimicamente , Disfunção Ventricular Esquerda/etiologia , Idoso , Amiodarona/uso terapêutico , Antiarrítmicos/uso terapêutico , Evolução Fatal , Humanos , Masculino , Infarto do Miocárdio/terapia , Índice de Gravidade de Doença , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/terapia , Disfunção Ventricular Esquerda/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA